CD34+CD19-CD22+ B细胞祖细胞可能是CD19靶向治疗患者表型逃逸的基础
CD19靶向免疫治疗虽使晚期B细胞急性淋巴细胞白血病(B-ALL)获得高完全缓解率,但许多患者最终复发。研究发现CD22表达早于CD19,约70%的B-ALL患者诊断和复发骨髓样本中存在CD34+CD19-CD22+细胞,且CD19 CAR T细胞治疗后完全缓解患者中该细胞频率增加两倍。CD19靶向免疫治疗后复发患者治疗前CD34+CD19-CD22+细胞中位数高3倍。荧光原位杂交和异种移植模型显示这些细胞携带诊断时的遗传学异常并在体内启动白血病发生。数据表明前白血病性CD34+CD19-CD22+祖细胞是CD19靶向免疫治疗后表型逃逸的基础,支持CD19/CD22双靶向临床研究,并鼓励在临床实验室中对B-ALL患者初始诊断和CD19靶向治疗期间监测时实施CD34/CD19/CD22免疫表型分析。
要点
- CD22表达早于CD19,CD34+CD19-CD22+细胞存在于约70%的B-ALL患者诊断和复发骨髓中。
- CD19 CAR T细胞治疗后完全缓解患者中CD34+CD19-CD22+细胞频率增加两倍。
- CD19靶向免疫治疗后复发患者治疗前CD34+CD19-CD22+细胞中位数高3倍(中位随访24个月)。
核心结论
- 前白血病性CD34+CD19-CD22+祖细胞可能是CD19靶向免疫治疗后表型逃逸的基础。
- 数据支持CD19/CD22双靶向作为减少CD19阴性复发的策略。
- 鼓励在临床实验室中对B-ALL患者初始诊断和CD19靶向治疗期间监测时实施CD34/CD19/CD22免疫表型分析。
研究设计与样本
- 研究B-ALL患者诊断和复发骨髓样本中CD34+CD19-CD22+细胞。
- 采用荧光原位杂交分析流式分选细胞群和异种移植模型。
- 中位随访24个月。
主要发现
- CD22表达早于CD19表达。
- CD34+CD19-CD22+细胞存在于约70%的B-ALL患者诊断和复发骨髓样本中。
- CD19 CAR T细胞治疗后完全缓解的B-ALL患者中CD34+CD19-CD22+细胞频率增加两倍。
- CD19靶向免疫治疗后复发患者治疗前CD34+CD19-CD22+细胞中位数高3倍。
- CD34+CD19-CD22+细胞携带诊断时存在的遗传学异常并在体内启动白血病发生。
临床怎么用
- 鼓励在临床实验室中对B-ALL患者初始诊断和CD19靶向治疗期间监测时实施CD34/CD19/CD22免疫表型分析。
- 数据支持CD19/CD22双靶向作为减少CD19阴性复发的策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD19-directed immunotherapies have revolutionized the treatment of advanced B-cell acute lymphoblastic leukemia (B-ALL). Despite initial impressive rates of complete remission (CR) many patients ultimately relapse. Patients with B-ALL successfully treated with CD19-directed T cells eventually relapse, which, coupled with the early onset of CD22 expression during B-cell development, suggests that preexisting CD34+CD22+CD19- (pre)-leukemic cells represent an "early progenitor origin-related" mechanism underlying phenotypic escape to CD19-directed immunotherapies. We demonstrate that CD22 expression precedes CD19 expression during B-cell development. CD34+CD19-CD22+ cells are found in diagnostic and relapsed bone marrow samples of ∼70% of patients with B-ALL, and their frequency increases twofold in patients with B-ALL in CR after CD19 CAR T-cell therapy. The median of CD34+CD19-CD22+ cells before treatment was threefold higher in patients in whom B-ALL relapsed after CD19-directed immunotherapy (median follow-up, 24 months). Fluorescence in situ hybridization analysis in flow-sorted cell populations and xenograft modeling revealed that CD34+CD19-CD22+ cells harbor the genetic abnormalities present at diagnosis and initiate leukemogenesis in vivo. Our data suggest that preleukemic CD34+CD19-CD22+ progenitors underlie phenotypic escape after CD19-directed immunotherapies and reinforce ongoing clinical studies aimed at CD19/CD22 dual targeting as a strategy for reducing CD19- relapses. The implementation of CD34/CD19/CD22 immunophenotyping in clinical laboratories for initial diagnosis and subsequent monitoring of patients with B-ALL during CD19-targeted therapy is encouraged.
引用
- Bueno C, Barrera S, Bataller A, et al. CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies. Blood. 2022. PMID: 35421218. doi:10.1182/blood.2021014840
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。